Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
152
days
Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection
Authors
Johanna Vikkula; Kari Remes; Outi Laatikainen; Merja Utriainen; Saara Tikka; Juha LievonenShow moreShow less
Affiliations
1. Medaffcon Oy, Espoo, Finland; 2. Turku University, Turku, Finland; 3. GSK Oy, Helsinki, Finland; 4. Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, FinlandShow moreShow less
148
days
Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA
Authors
Catherine C. Coombs; Thomas W. LeBlanc; Katherine B. Winfree; Catherine E. Muehlenbein; Urvi Desai; Noam Y. Kirson; Ashley Holub; Alice Qu; Ellen Sears; Brian Koffman; Meghan C. ThompsonShow moreShow less
Affiliations
1. University of California Irvine School of Medicine, Irvine, CA, USA; 2. Duke University School of Medicine, Durham, NC, USA; 3. Eli Lilly and Company, Indianapolis, IN, USA; 4. Analysis Group Inc., Boston, MA, USA; 5. CLL Society, Chula Vista, CA, USA; 6. Memorial Sloan Kettering Cancer Center, New York, NY, USAShow moreShow less
304
days
BEAC Induction Regimen and Prior Thoracic Radiotherapy Increases the Risk of ASCT-Associated Pneumonitis
Authors
Elina Kaprio; Anna Jokimäki; Hanne Kuitunen; Joel Kontiainen; Tuomas Selander; Taina Turpeenniemi-Hujanen; Outi KuittinenShow moreShow less
Affiliations
1. Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, Kuopio, Finland; 2. Central Hospital of Southern Osthrobotnia, Seinäjoki, Finland; 3. Oulu University Hospital, Medical Research Center and Cancer Centre, Oulu University Hospital, Oulu, Finland; 4. Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland; 5. Science Service Center, Kuopio University Hospital, Kuopio, Finland; 6. University of Oulu, Translational Medicine Research Unit, Oulu, Finland; 7. Kuopio University Hospital, Cancer Center, Kuopio, FinlandShow moreShow less
191
days
Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study
Authors
Margaret T. Kasner; Nigel Courtenay-Luck; Courtney D. DiNardo; Sean M. Post; Praneeth Baratam; George N. Magrath; Takaaki Nakamura; Akifumi Fujii; Sergio Prados; Naoki Honda; Mary McBride; Paula Edwards-Holmes; Robert StuartShow moreShow less
Affiliations
1. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; 2. Ono Pharma UK Ltd., London, UK; 3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4. Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA; 5. Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA; 6. Ono Pharmaceutical Co., Ltd., Osaka, Japan; 7. Ono Pharma USA, Inc., Cambridge, MA, USAShow moreShow less
314
days
Patients with Prior Cerebral Venous Sinus Thrombosis Presenting to the Emergency Department with Neurological Symptoms: The Yield of Neuroimaging
Authors
Evgeny Grishin; Ivan Budnik; Orly Efros; Omri Cohen; Gili Kenet; Sarina Levy-Mendelovich; Assaf Arie BargShow moreShow less
Affiliations
1. Faculty of Medicinal and Health Sciences, Tel Aviv University, Tel Aviv, Israel; 2. Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 3. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; 4. National Hemophilia Center, Coagulation Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Ramat Gan, Israel; 5. Department of Medicine and Surgery, University of Insubria, Varese, Italy; 6. Talpiot Sheba Leadership Program, Sheba Medical Center, Ramat Gan, Israel; 7. Departmnet of Pediatric Hematology-Oncology, The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Ramat Gan, IsraelShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days